

**ACT No. 110**

2024 Regular Session

HOUSE BILL NO. 204

BY REPRESENTATIVES TURNER AND CHASSION

1 AN ACT

2 To amend and reenact R.S. 40:964(Schedule I)(F)(5), (6), and (26) and to enact R.S.  
3 40:964(Schedule I)(A)(101) through (105), (C)(69) through (72), (D)(8) through  
4 (10), and (F)(30) and (Schedule IV)(B)(59), relative to naming language and the  
5 composition of various schedules of controlled substances; and to provide for related  
6 matters.

7 Be it enacted by the Legislature of Louisiana:

8 Section 1. R.S. 40:964(Schedule I)(F)(5), (6), and (26) are hereby amended and  
9 reenacted and R.S. 40:964(Schedule I)(A)(101) through (105), (C)(69) through (72), (D)(8)  
10 through (10), and (F)(30) and (Schedule IV)(B)(59) are hereby enacted to read as follows:

11 §964. Composition of schedules

12 Schedules I, II, III, IV, and V shall, unless and until added pursuant to R.S.  
13 40:962, consist of the following drugs or other substances, by whatever official  
14 name, common or usual name, chemical name, or brand name designated:

15 SCHEDULE I

16 A. Opiates. Unless specifically excepted or unless listed in another schedule,  
17 any of the following opiates, including their isomers, esters, ethers, salts, or salts of  
18 isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers,  
19 or salts is possible within the specific chemical designation:

20 \* \* \*

21 (101) 2',5'-dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidine-  
22 4-yl)-N-phenylpropionamide)

23 (102) alpha'-methyl butyryl fentanyl (2-methyl-N-(1-phenethylpiperidin-4-yl)  
24 -N-phenylbutanamide)

1                   (103) para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-(1-  
2                   phenethylpiperidin-4-yl)furan-2-carboxamide)

3                   (104) para-methylcyclopropyl fentanyl (N-(4-methylphenyl)-N-  
4                   (1-phenethylpiperidin-4-yl)cyclopropanecarboxamide)

5                   (105) 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-  
6                   1-yl)butan-1-one)

7   \*       \*       \*

8                   C. Hallucinogenic substances. Unless specifically excepted or unless listed  
9                   in another schedule, any material, compound, mixture, or preparation, which  
10                  contains any quantity of the following hallucinogenic substances, or which contains  
11                  any of their salts, isomers, or salts of isomers, whenever the existence of such salts,  
12                  isomers, or salts of isomers is possible within the specific chemical designation, for  
13                  purposes of this Subsection only, the term "isomer" includes the optical, position,  
14                  and geometric isomers:

15   \*       \*       \*

16                   (69) 4-chloro-2,5-dimethoxyamphetamine

17                   (70) 4-iodo-2,5-dimethoxyamphetamine

18                   (71) 5-methoxy-alpha-methyltryptamine (5-MEO-AMT)

19                   (72) 5-methoxy-N,N-diethyltryptamine (5-MEO-DET)

20                  D. Depressants. Unless specifically excepted or unless listed in another  
21                  schedule, any material, compound, mixture, or preparation which contains any  
22                  quantity of the following substances having a depressant effect on the central  
23                  nervous system, including its salts, isomers, and salts of isomers whenever the  
24                  existence of such salts, isomers, and salts of isomers is possible within the specific  
25                  chemical designation:

26   \*       \*       \*

27                   (8) Diclazepam

28                   (9) Flubromazolam

29                   (10) Bromazolam

30   \*       \*       \*

1 F. Synthetic cannabinoids. Unless specifically excepted, or contained within  
 2 a pharmaceutical product approved by the United States Food and Drug  
 3 Administration, or unless listed in another schedule, any material, compound,  
 4 mixture, or preparation which contains any quantity of a synthetic cannabinoid found  
 5 to be in any of the following individual compounds or chemical groups, or any of  
 6 those individual compounds or groups which contain any synthetic cannabinoid salts,  
 7 isomers, salts of isomers, or nitrogen-heterocyclic analogs, whenever the existence  
 8 of such salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs is possible  
 9 within the specific compounds or chemical groups:

10 \* \* \*

11 (5) Butaldehydeamidoindoles: Any compound containing a  
 12 N-(1-oxobutan-2yl)-1H-indole-3-carboxamide structure, with or without substitution  
 13 on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide,  
 14 ~~arylhalkylhalide~~ alkylarylhalide, cycloalkylmethyl, cycloalkylethyl, alkenyl,  
 15 haloalkenyl, aliphatic alcohol, hydroxyl, halide, morpholinoethyl,  
 16 alkylmorpholinomethyl, alkylpiperidinylmethyl or a tetrahydropyranylmethyl group,  
 17 whether or not further substituted on the butaldehyde group to any extent.

18 (6) Cumylindolecarboxamides: Any compound containing a  
 19 N-(2-phenylpropane-2-yl)-1H-indole-3-carboxamide structure, with or without  
 20 substitution on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl  
 21 halide, ~~arylhalkylhalide~~ alkylarylhalide, cycloalkylmethyl, cycloalkylethyl, alkenyl,  
 22 haloalkenyl, aliphatic alcohol, hydroxyl, halide, morpholinoethyl,  
 23 alkylmorpholinomethyl, alkylpiperidinylmethyl or a tetrahydropyranylmethyl group,  
 24 whether or not further substituted on the phenyl group to any extent.

25 \* \* \*

26 (26) Phenylpropionaldehydeamidoindoles: Any compound containing a  
 27 N-(1-oxo-3-phenylpropan-2yl)-1H-indole-3-carboxamide structure, with or without  
 28 substitution on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl  
 29 halide, ~~arylhalkylhalide~~ alkylarylhalide, cycloalkylmethyl, cycloalkylethyl, alkenyl,  
 30 haloalkenyl, aliphatic alcohol, hydroxyl, halide, morpholinoethyl,

